Liver-Pancreas Fat Deposition: Impact on Cardiometabolic Multimorbidity and Cardiac Dysfunction [0.03%]
肝胰脂肪沉积：对心血管代谢多病共存和心脏功能障碍的影响
Li-You Lian,Tianyi Xia,Zhong-Wei Chen et al.
Li-You Lian et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and pancreatic steatosis (PS) are interconnected ectopic fat conditions linked to cardiometabolic dysregulation. Their combined effect on...
Reply to 'Further Considerations on the MyWayUp Digital Intervention for Alcohol Use Disorder in Alcohol-Related Liver Disease' [0.03%]
关于“与酒精相关性肝病的酒瘾患者数字干预方法MyWayUp进一步考虑”的回复
Clara Oliveras,Hugo López-Pelayo
Clara Oliveras
Novel Long-Read Sequencing Method for Characterisation of Hepatitis B Transcripts Show High Expression of Chimeric HBV/Human RNA [0.03%]
一种用于表征乙肝转录本的新长读测序方法显示出高水平的HBV/人类嵌合rna表达
Joakim Bedner Stenbäck,Johan Ringlander,Maria Andersson et al.
Joakim Bedner Stenbäck et al.
Background: Hepatitis B virus (HBV) genomes integrated into human DNA significantly contribute to surface antigen (HBsAg) production and may drive hepatocellular carcinoma (HCC). Long-read sequencing methods like Nanopore...
Liver Metabolomic Profiling Reveals Distinct Signatures Between Steatosis and Metabolic Dysfunction-Associated Steatohepatitis [0.03%]
肝脏代谢组学特征揭示了单纯性脂肪肝和代谢紊乱相关非酒精性脂肪性肝炎之间的差异
Saana Palomurto,Emily Flam,Dorota Kaminska et al.
Saana Palomurto et al.
Background and aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), the most common chronic liver disease worldwide, is closely linked to obesity and metabolic syndrome. The reason some patients with MA...
Low Serum sRAGE and MASLD Are Associated and Share a Similar Gut Microbiota Profile: A Prospective and Cross-Sectional Analysis [0.03%]
血清sRAGE与MASLD相关且具有相似的肠道微生物群谱：一项前瞻性及横断面分析
Laura Sol Grinshpan,Dana Ivancovsky-Wajcman,Oren Tirosh et al.
Laura Sol Grinshpan et al.
Background/aims: The pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) is multifactorial, with evidence suggesting a protective role for the soluble receptor for advanced glycation end-produ...
Particle Radiation Therapy With Immunotherapy for Advanced Hepatocellular Carcinoma: Emerging Evidence and Remaining Questions [0.03%]
粒子放疗联合免疫治疗用于晚期肝细胞癌：新兴证据和遗留问题
Takeshi Hatanaka,Kei Shibuya,Yuhei Miyasaka et al.
Takeshi Hatanaka et al.
Two-Step MRI and Clinical Model for Detecting At-Risk Steatohepatitis in Metabolic Liver Disease [0.03%]
代谢性肝病中检测风险NASH的两步MRI和临床模型
Mingkai Li,Zebin Chen,Haimei Chen et al.
Mingkai Li et al.
Background & aims: Identifying at-risk metabolic dysfunction-associated steatohepatitis (MASH with ≥ stage 2 fibrosis) is critical. While the steatosis-associated fibrosis estimator (SAFE) score effectively stages signif...
Response: Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC [0.03%]
纳武单抗联合伊匹木单抗治疗阿特朱单抗联合贝伐珠单抗治疗失败的晚期肝细胞癌患者：一项多中心、单组Ⅱ期试验
Jung Sun Kim,Thomas Yau,Hong Jae Chon
Jung Sun Kim
Validated Nationwide Scoring System for Hepatocellular Carcinoma Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease [0.03%]
代谢功能障碍相关肝脂肪变性肝病发生肝细胞癌风险的全国范围内验证评分系统
Teng-Yu Lee,Sherlot Juan Song,Hsiu J Ho et al.
Teng-Yu Lee et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent; however, MASLD-related hepatocellular carcinoma (HCC) has a relatively low incidence, posing a public health challen...
Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights [0.03%]
慢性乙型肝炎不确定期/灰色地带：临床特征、结局和分子机制洞察
Maria Stella Franzè,Teresa Pollicino,Jean-Michel Pawlotsky et al.
Maria Stella Franzè et al.
Chronic hepatitis B virus (HBV) infection remains a global public health challenge, with a high risk of complications such as cirrhosis, hepatocellular carcinoma (HCC) and death. As outlined in current international society guidelines, anti...